Trials / Completed
CompletedNCT00088270
A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (planned)
- Sponsor
- OSI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSI-7904L | |
| DRUG | 5-Fluorouracil/Leucovorin |
Timeline
- Start date
- 2004-08-01
- Completion
- 2005-08-01
- First posted
- 2004-07-26
- Last updated
- 2006-02-22
Locations
21 sites across 6 countries: United States, Belgium, Germany, Poland, Romania, Switzerland
Source: ClinicalTrials.gov record NCT00088270. Inclusion in this directory is not an endorsement.